8/9/2019 Comparative Study of Cefpodoxime and to study the market potential for RANBAXYs product portfolio

1/11

Comparative study of Cefpodoxime

and to study the market potential for

s product portfolio.

8/9/2019 Comparative Study of Cefpodoxime and to study the market potential for RANBAXYs product portfolio

2/11

Started by RanbirSingh and Gurbax

Singh 1937

Incorporated in

1961 and wentpublic in 1973

June 2008, withDaiichi Sankyo

Ranbaxy & DaiichiSankyo combinedrank top 20 globalpharmaceuticalcompanies.

In public

Merger

Position

No. 1 Indian PharmaCompanyGlobal consolidatedsales US $ 1519 Mn(2009)International 77%

Domestic 23%

8/9/2019 Comparative Study of Cefpodoxime and to study the market potential for RANBAXYs product portfolio

3/11

Ginseng

Ofloxacin

Valacyclovir

Ciprofloxacin

Diclofenac

Amoxycillin

CefpodoximeAtorvastatin

Cephalexin

CeftriaxoneIsotretinoin

Rantidine

ImipenemCo-amoxyclav

LoratadineKetorolac

Simvastatin

8/9/2019 Comparative Study of Cefpodoxime and to study the market potential for RANBAXYs product portfolio

4/11

(Cefpodoxime proxetil) is an orallyadministered, extended spectrum, semi-syntheticantibiotic of the cephalosporin class.

Microbiology:Cefpodoxime is active against a wide spectrum of Gram-positive and Gram-negative bacteria. Cefpodoxime is stable in the presence of beta-lactamaseenzymes. As a result, many organisms resistant to penicillins andcephalosporins, due to their production of beta-lactamase, may be susceptibleto cefpodoxime.

FOR PRODUCT PORTFOLIO CEPODEM-XP (Cefpodoxime + Clavulanic Acid) CEROXIM (Cefuroxime) CEROXIM-XP (Cefuroxime + Clavulanic Acid) RACIPER (Esomeprazole) RICONIA (Multivitamin) ALTRAFLAM (Aceclofenac) SYNASMA (Doxofylline) & GEMBAX (Gemifloxacin)

8/9/2019 Comparative Study of Cefpodoxime and to study the market potential for RANBAXYs product portfolio

5/11

To know the market share of theRanbaxys Products in Ranbaxy

(Pharma) Section.

To know about the current products thatare giving a tough competition toRanbaxy.

To know about the new competitors thathave entered into the market and aretrying to capture some of its share.

1

2

3

8/9/2019 Comparative Study of Cefpodoxime and to study the market potential for RANBAXYs product portfolio

6/11

Type of Research: Exploratory research

Sample unit: Retailer

Sample extent: South Delhi

Sampling technique: Convenient sampling

Sample size: 100 Retailers

Data collection methods:

Primary methods: (a)Face to face interactions (b) Questionnaire

Secondary methods: Company manuals ,Journals ,Magazines & Internet

Analysis techniqueMicrosoft Excel has been used for the statistical analysis.

Limitations:

Sometime respondents refuse to cooperate and it may possible that theygive biased and dishonest answers.

8/9/2019 Comparative Study of Cefpodoxime and to study the market potential for RANBAXYs product portfolio

7/11

SALE OF CEPODEM STRIP/WEEK

8/9/2019 Comparative Study of Cefpodoxime and to study the market potential for RANBAXYs product portfolio

8/11

0

10

20

30

40

50

60

70

80

90

CEPODEM CEPODEM-XP CEROXIM CEROXIM-XP RACIPER RICONIA ALTRAFLAM-P SYNASMA GEMBAX

Ranbaxy Product sales/week

OVERALL AIIMS MALVIYA NAGAR CHITTARANJAN PARK

JANGPURA---BHOGAL NEW FRIENDS COLONY JAMIA NAGAR(OKHLA) OKHLA (FORTIS HOSPITAL)

8/9/2019 Comparative Study of Cefpodoxime and to study the market potential for RANBAXYs product portfolio

9/11

8/9/2019 Comparative Study of Cefpodoxime and to study the market potential for RANBAXYs product portfolio

10/11

Cost factor

Advertisement in medical journals.

More profit and replacementschemes to the chemists

Availability of products

Frequent Doctors Visit.

8/9/2019 Comparative Study of Cefpodoxime and to study the market potential for RANBAXYs product portfolio

11/11